Charles River Expands NGS Services with Arovella Therapeutics Deal — Charles River Laboratories International, Inc.

Event summary

Charles River Laboratories (NYSE: CRL) collaborates with Arovella Therapeutics to provide GMP Next Generation Sequencing (NGS) services for cell characterization.
FDA approved the use of NGS for viral safety testing in Arovella’s IND application for its iNKT cell therapy platform.
Charles River will perform viral safety release testing on clinical batches of ALA-101, a CAR-iNKT cell therapy targeting CD19+ B cell lymphomas and leukemias.
Charles River recently acquired Pathoquest to enhance NGS capabilities.

The big picture

This collaboration underscores the growing importance of NGS in advancing cell and gene therapies, particularly as regulatory bodies like the FDA validate its use. The deal aligns with broader industry trends toward safer, more efficient development processes for advanced therapeutics. Charles River’s acquisition of Pathoquest further solidifies its position as a leader in sequencing solutions, enhancing its ability to meet stringent regulatory requirements.

What we're watching

Regulatory Validation: How the FDA’s acceptance of NGS in Arovella’s IND will influence broader adoption of modern sequencing methods in cell and gene therapies.
Execution Risk: Whether Charles River can sustain its strategic goal to deliver enhanced client experiences through advanced NGS services.
Market Expansion: The pace at which Charles River integrates Pathoquest’s capabilities to accelerate sequencing-based testing across the development pipeline.